MicroRNA profiling identifies a novel compound with antidepressant properties

Stacy Sell, Deborah R. Boone, Harris A. Weisz, Cesar Cardenas, Hannah E. Willey, Ian J. Bolding, Maria Micci, Michael T. Falduto, Karen E.O. Torres, Douglas Dewitt, Donald Prough, Helen Hellmich

Research output: Contribution to journalArticle

Abstract

Patients with traumatic brain injury (TBI) are frequently diagnosed with depression. Together, these two leading causes of death and disability significantly contribute to the global burden of healthcare costs. However, there are no drug treatments for TBI and antidepressants are considered off-label for depression in patients with TBI. In molecular profiling studies of rat hippocampus after experimental TBI, we found that TBI altered the expression of a subset of small, non-coding, microRNAs (miRNAs). One known neuroprotective compound (17β-estradiol, E2), and two experimental neuroprotective compounds (JM6 and PMI-006), reversed the effects of TBI on miRNAs. Subsequent in silico analyses revealed that the injury-altered miRNAs were predicted to regulate genes involved in depression. Thus, we hypothesized that drug-induced miRNA profiles can be used to identify compounds with antidepressant properties. To confirm this hypothesis, we examined miRNA expression in hippocampi of injured rats treated with one of three known antidepressants (imipramine, fluoxetine and sertraline). Bioinformatic analyses revealed that TBI, potentially via its effects on multiple regulatory miRNAs, dysregulated transcriptional networks involved in neuroplasticity, neurogenesis, and circadian rhythms- networks known to adversely affect mood, cognition and memory. As did E2, JM6, and PMI-006, all three antidepressants reversed the effects of TBI on multiple injury-altered miRNAs. Furthermore, JM6 reduced TBI-induced inflammation in the hippocampus and depression-like behavior in the forced swim test; these are both properties of classic antidepressant drugs. Our results support the hypothesis that miRNA expression signatures can identify neuroprotective and antidepressant properties of novel compounds and that there is substantial overlap between neuroprotection and antidepressant properties.

Original languageEnglish (US)
Article numbere0221163
JournalPloS one
Volume14
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

antidepressants
MicroRNAs
microRNA
Antidepressive Agents
Brain
brain
hippocampus
Depression
Hippocampus
Rats
health care costs
Drug therapy
Traumatic Brain Injury
Sertraline
Neuronal Plasticity
neurogenesis
Imipramine
Multiple Trauma
Gene Regulatory Networks
Fluoxetine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Sell, S., Boone, D. R., Weisz, H. A., Cardenas, C., Willey, H. E., Bolding, I. J., ... Hellmich, H. (2019). MicroRNA profiling identifies a novel compound with antidepressant properties. PloS one, 14(8), [e0221163]. https://doi.org/10.1371/journal.pone.0221163

MicroRNA profiling identifies a novel compound with antidepressant properties. / Sell, Stacy; Boone, Deborah R.; Weisz, Harris A.; Cardenas, Cesar; Willey, Hannah E.; Bolding, Ian J.; Micci, Maria; Falduto, Michael T.; Torres, Karen E.O.; Dewitt, Douglas; Prough, Donald; Hellmich, Helen.

In: PloS one, Vol. 14, No. 8, e0221163, 01.01.2019.

Research output: Contribution to journalArticle

Sell, S, Boone, DR, Weisz, HA, Cardenas, C, Willey, HE, Bolding, IJ, Micci, M, Falduto, MT, Torres, KEO, Dewitt, D, Prough, D & Hellmich, H 2019, 'MicroRNA profiling identifies a novel compound with antidepressant properties', PloS one, vol. 14, no. 8, e0221163. https://doi.org/10.1371/journal.pone.0221163
Sell S, Boone DR, Weisz HA, Cardenas C, Willey HE, Bolding IJ et al. MicroRNA profiling identifies a novel compound with antidepressant properties. PloS one. 2019 Jan 1;14(8). e0221163. https://doi.org/10.1371/journal.pone.0221163
Sell, Stacy ; Boone, Deborah R. ; Weisz, Harris A. ; Cardenas, Cesar ; Willey, Hannah E. ; Bolding, Ian J. ; Micci, Maria ; Falduto, Michael T. ; Torres, Karen E.O. ; Dewitt, Douglas ; Prough, Donald ; Hellmich, Helen. / MicroRNA profiling identifies a novel compound with antidepressant properties. In: PloS one. 2019 ; Vol. 14, No. 8.
@article{0d0b4d62aa7641c58f3c48efa5ab43e5,
title = "MicroRNA profiling identifies a novel compound with antidepressant properties",
abstract = "Patients with traumatic brain injury (TBI) are frequently diagnosed with depression. Together, these two leading causes of death and disability significantly contribute to the global burden of healthcare costs. However, there are no drug treatments for TBI and antidepressants are considered off-label for depression in patients with TBI. In molecular profiling studies of rat hippocampus after experimental TBI, we found that TBI altered the expression of a subset of small, non-coding, microRNAs (miRNAs). One known neuroprotective compound (17β-estradiol, E2), and two experimental neuroprotective compounds (JM6 and PMI-006), reversed the effects of TBI on miRNAs. Subsequent in silico analyses revealed that the injury-altered miRNAs were predicted to regulate genes involved in depression. Thus, we hypothesized that drug-induced miRNA profiles can be used to identify compounds with antidepressant properties. To confirm this hypothesis, we examined miRNA expression in hippocampi of injured rats treated with one of three known antidepressants (imipramine, fluoxetine and sertraline). Bioinformatic analyses revealed that TBI, potentially via its effects on multiple regulatory miRNAs, dysregulated transcriptional networks involved in neuroplasticity, neurogenesis, and circadian rhythms- networks known to adversely affect mood, cognition and memory. As did E2, JM6, and PMI-006, all three antidepressants reversed the effects of TBI on multiple injury-altered miRNAs. Furthermore, JM6 reduced TBI-induced inflammation in the hippocampus and depression-like behavior in the forced swim test; these are both properties of classic antidepressant drugs. Our results support the hypothesis that miRNA expression signatures can identify neuroprotective and antidepressant properties of novel compounds and that there is substantial overlap between neuroprotection and antidepressant properties.",
author = "Stacy Sell and Boone, {Deborah R.} and Weisz, {Harris A.} and Cesar Cardenas and Willey, {Hannah E.} and Bolding, {Ian J.} and Maria Micci and Falduto, {Michael T.} and Torres, {Karen E.O.} and Douglas Dewitt and Donald Prough and Helen Hellmich",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0221163",
language = "English (US)",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - MicroRNA profiling identifies a novel compound with antidepressant properties

AU - Sell, Stacy

AU - Boone, Deborah R.

AU - Weisz, Harris A.

AU - Cardenas, Cesar

AU - Willey, Hannah E.

AU - Bolding, Ian J.

AU - Micci, Maria

AU - Falduto, Michael T.

AU - Torres, Karen E.O.

AU - Dewitt, Douglas

AU - Prough, Donald

AU - Hellmich, Helen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with traumatic brain injury (TBI) are frequently diagnosed with depression. Together, these two leading causes of death and disability significantly contribute to the global burden of healthcare costs. However, there are no drug treatments for TBI and antidepressants are considered off-label for depression in patients with TBI. In molecular profiling studies of rat hippocampus after experimental TBI, we found that TBI altered the expression of a subset of small, non-coding, microRNAs (miRNAs). One known neuroprotective compound (17β-estradiol, E2), and two experimental neuroprotective compounds (JM6 and PMI-006), reversed the effects of TBI on miRNAs. Subsequent in silico analyses revealed that the injury-altered miRNAs were predicted to regulate genes involved in depression. Thus, we hypothesized that drug-induced miRNA profiles can be used to identify compounds with antidepressant properties. To confirm this hypothesis, we examined miRNA expression in hippocampi of injured rats treated with one of three known antidepressants (imipramine, fluoxetine and sertraline). Bioinformatic analyses revealed that TBI, potentially via its effects on multiple regulatory miRNAs, dysregulated transcriptional networks involved in neuroplasticity, neurogenesis, and circadian rhythms- networks known to adversely affect mood, cognition and memory. As did E2, JM6, and PMI-006, all three antidepressants reversed the effects of TBI on multiple injury-altered miRNAs. Furthermore, JM6 reduced TBI-induced inflammation in the hippocampus and depression-like behavior in the forced swim test; these are both properties of classic antidepressant drugs. Our results support the hypothesis that miRNA expression signatures can identify neuroprotective and antidepressant properties of novel compounds and that there is substantial overlap between neuroprotection and antidepressant properties.

AB - Patients with traumatic brain injury (TBI) are frequently diagnosed with depression. Together, these two leading causes of death and disability significantly contribute to the global burden of healthcare costs. However, there are no drug treatments for TBI and antidepressants are considered off-label for depression in patients with TBI. In molecular profiling studies of rat hippocampus after experimental TBI, we found that TBI altered the expression of a subset of small, non-coding, microRNAs (miRNAs). One known neuroprotective compound (17β-estradiol, E2), and two experimental neuroprotective compounds (JM6 and PMI-006), reversed the effects of TBI on miRNAs. Subsequent in silico analyses revealed that the injury-altered miRNAs were predicted to regulate genes involved in depression. Thus, we hypothesized that drug-induced miRNA profiles can be used to identify compounds with antidepressant properties. To confirm this hypothesis, we examined miRNA expression in hippocampi of injured rats treated with one of three known antidepressants (imipramine, fluoxetine and sertraline). Bioinformatic analyses revealed that TBI, potentially via its effects on multiple regulatory miRNAs, dysregulated transcriptional networks involved in neuroplasticity, neurogenesis, and circadian rhythms- networks known to adversely affect mood, cognition and memory. As did E2, JM6, and PMI-006, all three antidepressants reversed the effects of TBI on multiple injury-altered miRNAs. Furthermore, JM6 reduced TBI-induced inflammation in the hippocampus and depression-like behavior in the forced swim test; these are both properties of classic antidepressant drugs. Our results support the hypothesis that miRNA expression signatures can identify neuroprotective and antidepressant properties of novel compounds and that there is substantial overlap between neuroprotection and antidepressant properties.

UR - http://www.scopus.com/inward/record.url?scp=85071334683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071334683&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0221163

DO - 10.1371/journal.pone.0221163

M3 - Article

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0221163

ER -